Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Mar 12, 2018 11:40pm
91 Views
Post# 27704591

RE:RE:RE:RE:RE:Philippe Dubuc, chef de la direction financière de Theratech

RE:RE:RE:RE:RE:Philippe Dubuc, chef de la direction financière de Theratech
jfm1330 wrote:
SPCEO1 wrote: I am sure Luc is indeed ticked off about the lack of reimbursement from Quebec but I don't think he is so resentful as to not pursue approval for Trogarzo in Canada. But it makes economic sense to go first for Europe before turning attention to Canada given the size of the respective markets. Trogarzo will be sold in Canada in early 2020 if I had to guess. 


You know we have an expression in french here in Qubec that says you can walk and chew gum at the same time. I really think Tanguay is playing a little game here. That won't last because it would be unethical and he is a very honest guy, but he still wants to get his message across about Egrifta reimbursment.



The organizations that handle reimbursements are not the same as the ones that approve drugs in most juristriction, maybe quebec is odd! There is no obvious connection between the two issues.

Bullboard Posts